Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT05226338 | Evaluation of Relative Bioavailability of D-0502 Tablet in Healthy Female Subjects | PHASE1 | COMPLETED | 18 | — | — | Oct 27, 2021 | May 11, 2022 | Aug 8, 2022 | 1 | United States |
Access the oral bioavailability of D-0502 100mg and 200mg tablets relative to D-0502 50mg tablet formulation
| Arm | Type | Description |
|---|---|---|
| Sequence 1 | EXPERIMENTAL | 3 period, 3 dose level |
| Sequence 2 | EXPERIMENTAL | 3 period, 3 dose level |
| Sequence 3 | EXPERIMENTAL | 3 period, 3 dose level |
| Sequence 4 | EXPERIMENTAL | 3 period, 3 dose level |
| Sequence 5 | EXPERIMENTAL | 3 period, 3 dose level |
| Sequence 6 | EXPERIMENTAL | 3 period, 3 dose level |
| Name | Type | Description |
|---|---|---|
| D-0502 | DRUG | Formulation 1 Formulation 2 Formulation 3 |
Inclusion Criteria: * Healthy female subjects between the ages of 18-55 * Required evaluation by Investigator for screening and enrollment * Agreement and compliance with the study and follow-up procedures Exclusion Criteria: * Significant medical history or current comorbidly determined by the I...